The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
CONTEXT: Male hypogonadism is associated with visceral obesity and the metabolic syndrome: factors important for the development of nonalcoholic fatty liver disease (NAFLD). The Testosterone Trials (The T Trials) showed testosterone (T) treatment compared with placebo in older hypogonadal men was associated with decreases in cholesterol and insulin levels suggesting that T treatment may improve NAFLD.
OBJECTIVE: Compare effects of T vs placebo treatment on NAFLD scores and liver scans in elderly hypogonadal men.
METHODS: Secondary data analyses from 479 older hypogonadal men with total T < 275 ng/dL from The T Trials were performed. Three clinical liver fat scores-lipid accumulation product index, hepatic steatosis index, nonalcoholic fatty liver disease-metabolic syndrome score-and liver computed tomography (CT) Hounsfield units and liver to spleen ratio were evaluated at baseline and 12 months after treatment.
RESULTS: There were no statistically significant differences of change in lipid accumulation product index (P = .98), hepatic steatosis index (P = .67), and nonalcoholic fatty liver disease-metabolic syndrome (P = .52) in 246 men treated with T compared with 233 treated with placebo for 12 months. Liver CT showed no statistically significant difference of change in Hounsfield units (P = .24; n = 71 for T, n = 69 for placebo) and liver to spleen ratio (P = .74; n = 55 for T, n = 62 for placebo) between the 2 groups.
CONCLUSIONS: Our study did not show improvement of NAFLD in older hypogonadal men after 12 months of T vs placebo treatment, as assessed by 3 clinical scores and liver CT for hepatic steatosis. Future studies with longer treatment duration and additional NAFLD diagnostic modalities as primary outcome are warranted.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
---|---|
Enthalten in: |
The Journal of clinical endocrinology and metabolism - 109(2024), 2 vom: 18. Jan., Seite e757-e764 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lee, Hae Seung [VerfasserIn] |
---|
Links: |
---|
Themen: |
3XMK78S47O |
---|
Anmerkungen: |
Date Completed 19.01.2024 Date Revised 19.01.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1210/clinem/dgad511 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361537867 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM361537867 | ||
003 | DE-627 | ||
005 | 20240119231855.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1210/clinem/dgad511 |2 doi | |
028 | 5 | 2 | |a pubmed24n1264.xml |
035 | |a (DE-627)NLM361537867 | ||
035 | |a (NLM)37656011 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lee, Hae Seung |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.01.2024 | ||
500 | |a Date Revised 19.01.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a CONTEXT: Male hypogonadism is associated with visceral obesity and the metabolic syndrome: factors important for the development of nonalcoholic fatty liver disease (NAFLD). The Testosterone Trials (The T Trials) showed testosterone (T) treatment compared with placebo in older hypogonadal men was associated with decreases in cholesterol and insulin levels suggesting that T treatment may improve NAFLD | ||
520 | |a OBJECTIVE: Compare effects of T vs placebo treatment on NAFLD scores and liver scans in elderly hypogonadal men | ||
520 | |a METHODS: Secondary data analyses from 479 older hypogonadal men with total T < 275 ng/dL from The T Trials were performed. Three clinical liver fat scores-lipid accumulation product index, hepatic steatosis index, nonalcoholic fatty liver disease-metabolic syndrome score-and liver computed tomography (CT) Hounsfield units and liver to spleen ratio were evaluated at baseline and 12 months after treatment | ||
520 | |a RESULTS: There were no statistically significant differences of change in lipid accumulation product index (P = .98), hepatic steatosis index (P = .67), and nonalcoholic fatty liver disease-metabolic syndrome (P = .52) in 246 men treated with T compared with 233 treated with placebo for 12 months. Liver CT showed no statistically significant difference of change in Hounsfield units (P = .24; n = 71 for T, n = 69 for placebo) and liver to spleen ratio (P = .74; n = 55 for T, n = 62 for placebo) between the 2 groups | ||
520 | |a CONCLUSIONS: Our study did not show improvement of NAFLD in older hypogonadal men after 12 months of T vs placebo treatment, as assessed by 3 clinical scores and liver CT for hepatic steatosis. Future studies with longer treatment duration and additional NAFLD diagnostic modalities as primary outcome are warranted | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a aging | |
650 | 4 | |a male reproductive health | |
650 | 4 | |a nonalcoholic fatty liver | |
650 | 7 | |a Testosterone |2 NLM | |
650 | 7 | |a 3XMK78S47O |2 NLM | |
700 | 1 | |a Han, Sang Hun |e verfasserin |4 aut | |
700 | 1 | |a Swerdloff, Ronald |e verfasserin |4 aut | |
700 | 1 | |a Pak, Youngju |e verfasserin |4 aut | |
700 | 1 | |a Budoff, Matthew |e verfasserin |4 aut | |
700 | 1 | |a Wang, Christina |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 109(2024), 2 vom: 18. Jan., Seite e757-e764 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
773 | 1 | 8 | |g volume:109 |g year:2024 |g number:2 |g day:18 |g month:01 |g pages:e757-e764 |
856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgad511 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 109 |j 2024 |e 2 |b 18 |c 01 |h e757-e764 |